Coeptis Therapeutics Holdings, Inc.

As of December 31, 2025, Coeptis Therapeutics Holdings, Inc. has 5.75M shares outstanding.

These figures are as of December 31, 2025. The price-to-sales ratio is 40.16, and the price-to-book ratio stands at -0.50.

These figures are as of December 31, 2025. The EV/Sales ratio of 36.07 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative.

As of December 31, 2025, Coeptis Therapeutics Holdings, Inc. maintains a current ratio of 4.16, meaning it holds 4.2x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 1.91, indicating elevated leverage, while an interest coverage ratio of -18.40 demonstrates limited ability to service its debt obligations.

These figures cover the twelve months ended December 31, 2025. Return on assets (ROA) is negative at -87.06, reflecting losses generated across the asset base.

Over the twelve months ended December 31, 2025, Coeptis Therapeutics Holdings, Inc. posted a gross margin of 86.75, reflecting its pricing power and cost economics. The operating margin of -956.94 and net profit margin of -800.38 provide insight into operational efficiency.

These figures cover the twelve months ended December 31, 2025. Free cash flow yield is negative at -15.72: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -25.11, meaning Coeptis Therapeutics Holdings, Inc. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Coeptis Therapeutics Holdings, Inc.'s most recent stock split took place on December 31, 2024 with a 20:1 split ratio.

As of December 31, 2025, Coeptis Therapeutics Holdings, Inc. has an Altman Z-Score of 3.35, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.